Origin Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Origin Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-7,700	Closed	-$1.42M	–	138
2021 Q2	$1.42M	Hold	7,700	–	–	0.16%	53
2021 Q1	$1.18M	Sell	7,700 -7,000	-48%	-$1.08M	0.12%	67
2020 Q4	$2.3M	Hold	14,700	–	–	0.22%	36
2020 Q3	$1.68M	Sell	14,700 -8,100	-36%	-$874K	0.18%	42
2020 Q2	$2.56M	Sell	22,800 -1,900	-8%	-$202K	0.38%	33
2020 Q1	$2.22M	Sell	24,700 -36,000	-59%	-$3.53M	0.29%	38
2019 Q4	$6.57M	Hold	60,700	–	–	0.55%	51
2019 Q3	$5.95M	Sell	60,700 -9,000	-13%	-$1.01M	0.54%	54
2019 Q2	$9.13M	Sell	69,700 -35,500	-34%	-$4.58M	1.02%	33
2019 Q1	$14.2M	Buy	105,200 +19,200	+22%	+$2.39M	1.19%	38
2018 Q4	$8.37M	Buy	+86,000	New	+$10.2M	0.76%	53
2018 Q1	–	Sell	-56,500	Closed	-$6.76M	–	132
2017 Q4	$6.76M	Hold	56,500	–	–	0.39%	74
2017 Q3	$7.93M	Buy	+56,500	New	+$7.68M	0.49%	64
2015 Q2	–	Sell	-39,292	Closed	-$6.81M	–	116
2015 Q1	$6.81M	Hold	39,292	–	–	0.5%	73
2014 Q4	$7.27M	Sell	39,292 -23,208	-37%	-$4.3M	0.55%	70
2014 Q3	$10.4M	Hold	62,500	–	–	0.67%	61
2014 Q2	$9.77M	Buy	+62,500	New	+$9.87M	0.63%	66

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Origin Asset Management's ALXN Position: Q3 2021 in Review

Origin Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 7,700 shares — an estimated $1.42M sold.

Origin Asset Management first reported a position in ALXN in Q2 2014 and held it in 17 quarters. The position peaked at $14.2M in Q1 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Origin Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Origin Asset Management sold 7,700 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.42M.
Origin Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 17 quarters.
Origin Asset Management's Alexion Pharmaceuticals position peaked at $14.2M in Q1 2019.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Origin Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.